La radiación optimiza la actividad antitumoral de bloque de punto de control en modelos tumorales singeneicos
Sumithra Urs, Mary Anne Meade, Kevin Guley, Sarah Krueger, Alden Wong, Scott Wise, and Maryland Rosenfeld Franklin
Encuentro Anual de AALAS
Introducción y antecedentes
- More than 50 % of cancer patients receive some sort of radiation therapy during the course of their illness.
- While radiation treatment is a mainstay in clinical oncology, there is limited preclinical data in syngeneic models.
- The advent of image-guided small animal irradiators such as the Small Animal Radiation Research Platform (SARRP; Xstrahl) allow for use of targeted focal irradiation (RT) in a broad range of models.
- Here we evaluated the use of RT to broaden efficacy and response duration of immunomodulatory therapies. In the GL261-Luc glioblastoma model we also examined possible changes in lymphoid and myeloid immune cells by flow cytometry and looked at infiltration of CD4+ T cells by immunohistochemistry.